Asian Markets Rally as Micron and Qualcomm AI Outlook Lifts Global Tech Stocks 
Gold Drops Below $4,000 as Strong US Dollar and Fed Rate Hike Expectations Pressure Bullion 
White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak 
Booked to travel through the Middle East? Here’s why you shouldn’t cancel your flight 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Supreme Court Blocks 5th Circuit Ruling on Abortion Pill Access 
SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business 
Medicare to Cover GLP-1 Weight-Loss and Diabetes Drugs Starting July 1 
SpaceX, Charter Communications Explore Mobile Partnership to Expand Starlink Wireless Service 
Debate over H-1B visas shines spotlight on US tech worker shortages 
Stuck in a creativity slump at work? Here are some surprising ways to get your spark back 
OpenAI May Delay IPO to 2027 Amid $1 Trillion Valuation Goal 
Gold Prices Fall Below $4,000 as Strong Dollar, Fed Rate Hike Bets Weigh on Bullion 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
CDC Monitors U.S. Travelers After Hantavirus Outbreak on Luxury Cruise Ship 
Australia Jobs Growth Strengthens Rate Hike Outlook 
Time to buy local: war fuel price shocks reveal the folly of a long food supply chain 
Bubs Australia will manufacture and distribute Bubs’ Chinese-label goat milk infant formula in China according to new Chinese standards. under an agreement with Heilongjiang Ubeite Dairy Group (HUG).
The new standards will come into effect in February 2023 .
The “ultra-premium” infant formula has been specially developed for Chinese infants using easily-digestible A2 goat-milk protein, sn2 palmitate (OPO), lactoferrin prebiotics, and nucleotides.
HUG has started submission with the State Administration for Market Regulation (SAMR) to renew its registration in line with China’s new GB standards for exclusive use under the Bubs brand.
According to Kristy Carr, Bubs founder and CEO, they have built strong brand trust and loyalty with Chinese families through marketing and selling Bubs English label infant formula products via the crossborder eCommerce channel, which accounts for around 20 percent of total Chinese infant formula sales.
If approved by SAMR, the formula will give Bubs access to the remaining 80 percent of China’s $25.9 billion infant formula market.
Bubs will also enter into a joint venture agreement, where it will hold a 75 percent interest, with Zhitong Health Technology to distribute its Chinese label goat infant formula products.
Bubs Australia expects to launch its product in the second half of FY23, subject to receiving SAMR approval.
